 Long-term adjuvant therapy high-risk malignant melanoma interferon alpha Fifty-three high-risk melanoma patients stage patients stage II standard surgical intervention adjuvant therapy recombinant interferon rIFN therapy total period months Concomitant patients stage stage II identical stages prognostic factors adjuvant therapy efficacy rIFN alpha therapy difference relapse incidence overall survival rates patients stage II benefit long-term adjuvant rIFN therapy treatment period months incidence relapses comparison controls treatment incidence relapse equal treated control groups results study continuous low-dose rIFN therapy adjuvant treatment malignant melanoma